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Abstract: Immunoglobulin replacement therapy (IRT) is standard treatment for patients with primary immunodefi-
ciency (PID). Because most of the patients with PID will require long life-time immunoglobulin replacement therapy, 
the quality of the prescribed products is of utmost importance. The IRT is generally administered either intravenous-
ly (abbreviated IVIG), or subcutaneously (abbreviated SCIG). Both routes have been demonstrated to be effective. 
The preferred route may vary at different times during a given patient’s life. Options are therefore not fixed and the 
choice of route for immunoglobulin therapy will depend on several factors, including patient characteristics, clini-
cal indication, venous access, side effects, rural or remote location, treatment compliance and patient preference. 
Many years ago, immunoglobulin therapy was associated with side effects which may compromise patient’s compli-
ance and quality of life of the patients. Most of the side effects were related to impurities. Recently, major advances 
in the manufacturing process have been made and new processes, such as the Quality by design (QbD) approach 
were added into the manufacturing steps to ensure patients tolerability and safety. Due to the improved purity of 
the immunoglobulin products obtained by these processes, the incidence of side effects is lower, while the ways 
of administration of Ig therapy and the choice of the regimen has widened to suit patient’s preference and needs. 
Keywords: Intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG) primary immune deficiency 
(PID), safety, infection, efficacy, immunomodulation
Introduction
To date there are more than 200 different pri-
mary immunodeficiency diseases (PID) recog-
nized by the World Health Organization (WHO) 
[1] and about 60% of all PID cases are asso- 
ciated with hypogammaglobulinemia due to 
impaired antibody production, leading to an 
increased susceptibility to infection. The dis-
ease affects both adults and children. Although 
rare, it is considered as a serious medical con-
dition due to its propensity to expose patients 
to serious and fatal infections [2]. Chronic or 
recurrent upper and lower respiratory tract 
infections, sinusitis and otitis media are the 
most common type of infections. Severe bacte-
rial infections (SBIs) such as sepsis, meningitis, 
septic arthritis and osteomyelitis can also 
occur.
In order to prevent infections, patients with PID 
need long term immunoglobulin G (IgG) replace-
ment therapy (IRT). Individualization of IgG 
treatment provides optimal medical care and 
improve quality of life outcomes in patients by 
preserving organ function, and preventing 
infection-related death [3]. Immunoglobulin re- 
placement therapy can be tailored to suit indi-
vidual patient needs; it can be given either by 
intravenous (iv) or subcutaneous (sc) routes. 
Both routes have advantages and disadvanta- 
ges that should be considered when selecting 
patient’s treatment.
Because most of patients with PID will need 
long term IgG replacement therapy, efficacy and 
safety of prescribed IgG products have an out-
standing importance. Adverse events associa- 
ted with IgG administration could not only be 
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disturbing for the patients but they could also 
impact patients’ compliance and adherence to 
therapy. Today a key focus of IRT is to advance 
development in the manufacturing processes 
of IgG to ensure their purity and tolerability, 
while preserving their effectiveness. 
The main objectives of the present review are 
1) to discuss the treatment options with IRT for 
the individualization of care in patients with 
PID, 2) to provide new insights in the manufac-
turing processes of IVIG, 3) to describe the lat-
est advances in IVIG purification process 
according to a Quality by design process (Qbd) 
and how this process improves safety and tol-
erability of IVIG in patients. 
IRT for the management of patients with PID 
Immunoglobulin replacement therapy has been 
standard treatment for patients with PID since 
its first use by Burton in 1952 [4]. Since then, 
the choice of immunoglobulins has widened 
with different products and different routes of 
administration, making individualization of IRT 
possible nowadays. 
PIDs are characterized by a clinically heteroge-
neous group of diseases, and not all PID 
patients will require the same treatment strat-
egy with IgG substitution. The main goal of 
management of patients with PID is to estab-
lish the diagnosis and confirm the indication for 
a treatment by IRT. For those who require 
replacement therapy for PID, IRT has demon-
strated a positive impact on patients’ outcomes 
and on long term quality of life [5, 6]. This 
impact is particularly significant when the diag-
nosis of PID is made early and the IRT started 
before damages to organs occurs  as reported 
in several surveys [7]; it has been shown that 
once the patients begin receiving IVIG on a reg-
ular basis their health status improves rapidly, 
their activity limitations drop significantly and 
their quality of life improves dramatically [7]. 
According to current guidelines [8, 9], IRT 
should be restricted to patients with confirmed 
hypogammaglobulinemia [total IgG or IgG sub-
classes reduced] with documented recurrent 
bacterial infections. The IRT is generally admi- 
nistered either intravenously (IVIG), or subcuta-
neously (SCIG). Both routes have been demon-
strated to be effective [10]. IVIG infusions are 
usually given every three or four weeks. 
Although SCIG is typically administered weekly 
by infusion pump, administration by rapid push 
technique or more advanced technique such as 
facilitated (fSCIG) pre-infusion of recombinant 
human hyaluronidase (rHuPH20) may provide a 
greater convenience. Recent evidence sug-
gests that the latter mode of administration is 
safe and effective [11, 12] while allowing 
administration every 2 to 4 weeks, similarly to 
IVIG, using only one or two sites.
Understanding the difference between these 
options helps clinicians in their decision of the 
best treatment option for a given patient (Table 
1). While, the IV route results in an early peak of 
IgG immediately after the infusion, followed by 
a slow decline in antibody levels during the 
days that follow (half-life around 30 to 40 days), 
SCIG is absorbed more slowly into the blood-
stream via the lymphatic system and requires 
more frequent administrations than IVIG; thus, 
a less variable steady-state IgG level is main-
tained, which eliminates the peaks and troughs 
that occur with monthly IVIG therapy. 
There are advantages and disadvantages for 
each route (outlined in Table 2) and the pre-
ferred route may vary at different times during 
a given patient’s life. Options are therefore, not 
Table 1. Main differences between the different route of administrations of Immunoglobulins 
IVIg SCIg fSCIg Manual push
Venous access Yes No No No
Max infusion rate 300 mL/hr 40 mL/hr 160-300 mL/hr 1-2 mL/min
Max dose/hr 30 g 6.4-8 g/site 16-30 g NA
Infusion time/month 2.9 hr 5-6 hr 2.7 hr 3-6 hr
Training time for home 4-6 sessions over 
3-6 months
4-6 sessions over 1-6 
weeks
4-6 sessions over 2-6 
months
4 sessions over 
4 days
Peak/trough variation Large Minor (slightly more 
with fortnightly dosing)
Intermediate, dependent 
on treatment interval
Minor
Pump requirement No Yes Yes, high volume No
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Table 2. IV versus SC route: advantages and disadvantages
IV route Sub-cutaneous Route
Advantages
    Shorter infusion times     Home-based therapy: greater
    Ability to give large volume by infusion and allows for intermittent dosing (every 3-4 weeks)     Independence/increase patient’s autonomy IV access not possible
    Convenient when need to load quickly     Preferred option if poor venous access, side effects with IVIG
    Allow for High dose indication (eg immunomodulation neurology, Weight, Higher Trough needed-XLA, bronchiectasis)     Flexibility (children, Travel, logistics and work considerations)
    Less needles     Low risk of systemic side effects
    Less frequent infusions
    Less involvement of the patient (does not require patient training)
Disadvantages
    Requires venous access and trained personnel     Relatively small volume of infusion, requires frequent dosing (at least once a week)
    Systemic side effects (less frequent with new highly purified IVIG)     Difficult to maintain trough on maximal SCIg
    Ability to self-infuse requires patient reliability and compliance
    Local side effects (swelling, induration, local inflammation, itch), which are usually 
transient
Table 3. New generation IVIG manufacturing steps and role of each step according to the QbD approach
Process Platform Step number Role of the step Purification process step
Plasma Fractionation Process I Cryo separation Removal of vWF/FVIII complex
II Ethanol fractionation Removal of immunoglobulins from albumin
Immunoglobulin new generation (IGNG) process III Caprilic acid fractionation Clearance of non-Ig proteins (including procoagulant factors)
IV Activated carbon depth filtration Adsorption of caprylic acid
V Ultrafiltration I Final clearance of caprylic acid, Buffer exchange before chromatography
VI SD treatment Inactivation of enveloped virus
VII Anion exchange chromatography Clearance of IgA and IgM, Reduction of solvent and detergent
VIII Affinity chromatography Depletion of anti-A and anti-B hemagglutinins
IX Filtration Reduction of polymers and aggregates
X 20 nm Nanofiltration Retention of small viruses
XI* Ultrafiltration Final clearance of solvent and detergent, clearance of chromatography buffer
XII* Formulation and filtration Addition of excipients, 0.2 µm filtration of the Purified Bulk Starting Material
*Specific process steps for 5% or 10% IVIG.
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fixed and the choice of route for IRT will depend 
on several factors, including patient character-
istics, clinical indication, venous access, side 
effects, rural or remote location, treatment 
plan compliance, patient preference and life 
style [13].
While subcutaneous route may be attractive for 
some patients because of reduced side effects, 
flexibility and ease of administration, patient 
education and training at the initiation of SCIG 
therapy is required, and a follow up is neces-
sary to ensure patient safety and effective 
treatment delivery. The IV route requires less 
frequent infusions, with the ability to give a 
large volume of IgG, which may be more appro-
priate in certain indications where higher doses 
are needed. Most patients tolerate IVIG very 
well. Infusions can be administered either in an 
outpatient clinic or, after tolerability and safety 
is demonstrated in the patient’s own home. 
SCIG therapy is generally indicated for patients 
with limited venous access and/or who have 
systemic adverse reactions to IVIG.
Immunoglobulin therapy side effects and rela-
tion to product manufacturing process
During IVIG replacement therapy in PID pa- 
tients, adverse reactions may occur; these side 
effects are generally minor such as chills and 
fever, other side effects although rare, can be 
serious such as anaphylactic shock, thrombo-
sis or hemolysis. Some of these side effects 
are related to the manufacturing process or the 
quality of the product such as the presence of 
impurities. Side effects that are related to 
impurities vary depending upon each IVIG puri-
fication process which is unique and specific to 
each product. Potential adverse events due to 
various constituents (e.g. Anti A/Anti B hemag-
glutinins, anti D, Polymers, IgA content, FXIa or 
other pro-coagulant proteins) can only be 
addressed if they are known and thus the 
strategic reduction of these within the manu-
facturing process is of utmost importance. 
The Ig production process involves steps of 
fractionation and purification of plasma. Dif- 
ferent methods for the purification of plasma 
and several approved methods for viral removal 
and inactivation are used by the immunoglobu-
lin manufacturers. Each step in the processing 
of plasma may cause alterations in its protein 
structure and its biological activity. As a conse-
quence, commercial preparations of Ig can dif-
fer in tolerability and efficacy related to protein 
structure and biological activity [14].
The WHO requirement for safety and quality of 
IVIG preparations was first established in 1982 
[15]. Since then, the manufacturing processes 
of Ig have evolved and continuous improve-
ment of analytical methods and manufacturing 
process for the development of highly purified 
human immunoglobulins is being performed in 
order to ensure that Ig are safe while maintain-
ing their structural and functional integrity. One 
of the approach to enhance the quality of IgG 
products is the so called “Quality by design 
(QbD) approach” [16] which is a science and 
risk-based methodology for product and pro-
cess development. The targeted product profile 
is implemented through a manufacturing pro-
cess of IVIG designed with each process step 
built to ensure product quality. For IVIG, the 
critical steps (see Table 3) include removal of 
activated coagulation factors to reduce the risk 
of thrombogenic adverse events, removal of IgA 
to avoid immune responses in patients defi-
cient in IgA; removal of anti-A and Anti-B hem-
agglutinins to avoid adverse events on patients 
of blood groups A, B or AB, reduction of aggre-
gates to avoid adverse events through comple-
ment activation and reduction of potential 
adventitious and non-adventitious agents by 
precipitation or chromatography and the use of 
dedicated steps such as solvent and detergent 
treatment and nanofiltration that contribute to 
reduce even more the risk of disease transmis-
sion and enhance biological safety of IVIG. The 
solvent/detergent technique is effective ag- 
ainst enveloped viruses, while nanofiltration 
removes both enveloped and non-enveloped 
viruses e.g. parvovirus B19 and hepatitis A 
[18]. These methods have been shown to pre-
serve the structural functions of the IgG while 
enhancing the tolerability and the quality of the 
IgG product [19].
In the recent years, companies developed li- 
quid solutions ready-to-use with higher concen-
trates of Ig such as 100 mg/mL solutions (10%) 
with a low pH that favors the stability of the 
product (pH: 4.3 to 5.0). Up to date 10% liquid 
formulations offer advantages because of their 
optimal pH, glycine or proline stabilizers, low 
sodium content, and physiological osmolality. 
They are also more convenient for the patient 
and health care provider for their ease of prep-
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aration and administration and short infusion 
duration [20].
Safety and efficacy of a new highly purified 
IVIG in the management of patients with PID
LFB has designed a novel purification process 
(the IGNG platform) based on the QbD approach 
for eliminating or reducing impurities in order to 
reduce the occurrence of adverse events, 
whilst maintaining the structural and functional 
integrity of IgG, and ensuring a constant batch 
to batch product quality based on a clear know- 
ledge of the process limits and a justified con-
trol strategy. ClairYg®, 5% liquid preparation 
licensed in France and other international mar-
kets, was the first product developed from the 
IGNG platform. Based on this experience, a 
10% liquid IVIG (IQYMUNE®) has also been 
developed. ClairYg® and IQYMUNE® share the 
same purification process with a different for-
mulation, 5% and 10% respectively. The cha- 
racteristics of these highly purified IVIG include 
the following: all IgG functionalities are pre-
served with IgG purity > 98%, low levels of IgA 
(≤ 28 μg/mL), low level of anti-A and anti-B 
hemagglutinins (8 to 16 and 4 to 8, respective-
ly, expressed as the inverse of the dilution), no 
detected activated factor XI (< 1.3 mIU/ml) or 
any pro-coagulant activity, use of 20 nm nano-
filtration and Solvent/Detergent treatment, are 
Saccharose- and maltose-free (stabilizer: glyci-
ne and polysorbate 80) formulated product at 
acidic pH (pH 4.8 ± 0.2). 
Here we report the results of a clinical trial tes-
ting the 10% ready- to-use liquid highly purified 
IVIG (nanofiltration 20 nm) (LFB biotechnolo-
gies) IQYMUNE® in patients with PID. In this 
open label, multicentric and prospective stu- 
dy, 62 patients with the diagnosis of X-linked 
agammaglobulinemia (XLA, n=20) or common 
variable immunodeficiency (CVID, n=42), were 
the EMA guideline on the clinical investigation 
of IVIG (EMA/CHMP/BPWP/94033/2007) [17], 
which recommends including at least 40 evalu-
able patients (20 adults and 20 children) for 
efficacy with a subgroup of 20 adult patients for 
PK analysis. This sample size was considered 
to allow at least an 80% power to reject the null 
hypothesis that the number of SBIs per patient 
and per year will be greater or equal to one with 
a type I error of 0.01 (one-sided test). It was 
assumed that the number of SBIs had a Poisson 
distribution. The model used to complete the 
primary analysis was an exact one-sided one-
sample Poisson test at significance level 0.01. 
The following hypotheses were tested: H0: per 
patient-year rate of SBIs > 1, H1: per patient-
year rate of SBIs < 1. The maximum likelihood 
estimator, the associated 2-sided 98% CI and 
the one-sided p-value of the exact test was pro-
vided. The null hypothesis was rejected if the 
upper bound of the CI was < 1. The point esti-
mates and CIs were presented by age group. 
Main secondary endpoints were annualized 
rate of all infections and infection-related 
parameters (absence from school or work, hos-
pitalization, antibiotic treatment) and safety 
and tolerability. 
There were 26 children and 36 adults enrolled, 
median age of children population was 11.5 
years (range: 2-17), and median age of adult 
patients was 40 years (range: 18-61). A total of 
56 patients were pretreated (56 IVIG, one SCIG) 
and 4 were Ig therapy naïve. Overall, the medi-
an baseline serum IgG through level was 5.78 
g/L (range: 0.45-9.99) and the mean number 
of serious bacterial infections (SBIs) in the pre-
vious year was 8 (12.9). In terms of efficacy, 
only one SBI (Acinetobacter bacteremia) was 
reported in a 24-year-old male CVID patient. 
This SBI occurred in a context of a very low IgG 
trough level (2.47 g/L) explained by an aggrava-
tion of a chronic enteropathy with protein loss. 
Table 4. Primary efficacy endpoint-Annualized number of SBIs
Pediatric (2-17)
N=26
Adults (≥ 18)
N=36
All
N=62
Nb of SBIs 0 1 1
Patient-year 26.37 31.37 57.74
SBI rate/patient/year 0.000 0.032 0.017
Two-sided 98% CI 0.000, 0.175 0.000, 0.212 0.000, 0.115
One-sided p-value - - < 0.001
SBI: Serious bacterial infections; CI: confidence interval.
enrolled to receive, IQYMUNE® at 
dose between 0.2 and 0.8 g/kg 
every 21 or 28 days for 12 
months. Patients had to be either 
naïve or previously treated with 
IVIG with stable dose of IVIG with 
at least 3 IgG through levels ≥ 4 
g/L within the last 6 months prior 
to study entry. The primary effica-
cy endpoint was the annualized 
number of serious bacterial infec-
tions (SBIs) per year as defined by 
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The patient completely recovered without any 
sequelae following antibiotic therapy. No SBI 
was reported in the pediatric population (Table 
4).
Overall, the annualized number of SBI was 
0.017 per patient (95% CI: 0.00; 0.115), which 
was significantly lower than the predefined 
threshold of 1.0 infection/patient/year) re- 
quired by EMA guidelines (p < 0.001). These 
results are also in line with the literature rang-
ing from 0.0 to 0.08 [17].
Regarding secondary endpoints, overall, 228 
infections were reported in 51/62 patients 
(82.3%), corresponding to a mean of 3.79 infec-
tions per patient/year, in line with the average 
range reported with other IVIGs [21, 22]. 
Infections were more frequent in the pediatric 
population (133 in 26 patients [100% of pediat-
rics]) than in adults (95 in 25 patients [69.4% of 
adults]). The difference in the rate of infections 
between pediatric and adult was expected. 
Usually, pediatric patients have more infections 
due to their childhood environment. As expect-
ed in the context of PID, most infections 
involved the respiratory tract; most frequently 
ones being bronchitis (30 infections in 24.2% 
of the patients), chronic sinusitis (28 infections 
in 14.5% of the patients), nasopharyngitis (26 
infections in 22.6% of the patients), and upper 
respiratory tract infections (18 infections in 
17.7% of the patients). Moreover, less infec-
tions were observed when IgG trough level was 
> 8 g/L (18.6% vs. 26.3% when IgG level ≤ 8 g/
dL, p=0.01).
Table 5 summarizes infection-associated 
parameters (infections, infections with use of 
antibiotics, hospitalization due to infection, and 
absence from work or school). As shown in the 
table, the rate of missed work or school days 
was low (8 patients for a total of 15 days). The 
annual number rate of days with use of antibiot-
ics per patient of 7.5 [95% IC: 12.7; 26.3]. Only 
five patients spent a total of 15 days at hospital 
due to infection. These results are comparable 
with the literature data on IVIG replacement 
therapy in patients with PID [21, 22]. 
Mean IgG trough levels in the total population 
over the period from the 6th infusion to the end 
of treatment was 7.76 g/L while the mean 
IQYMUNE® dose was 0.60 g/kg over the same 
period. Mean maximum infusion rate per 
patient (N=62) was 6.10 mL/kg/h [min-max 
1.00-8.00]. A total of 43.5% of patients (27/62) 
received at least one infusion at the maximum 
flow rate of 8 mL/kg/h. No patients received 
infusion at a rate > 8 mL/kg/h.
In terms of safety, thromboembolic events, 
renal complications, anaphylactic reactions or 
hemolysis were not reported. Headache, chills 
Table 5. Secondary efficacy endpoint-Infection associated parameters
All
N=62
Infections 
    Number of infections (nb of patients) 228 (51)
    Median annualised number of infections/patient (nb/year) [min-max] 3.0 [0.0-14.9]
    [95% IC] [2.88; 4.71]
Infections with antibiotic use
    Number of infections (nb of patients) 131 (38)
    Median annualized nb of days of antibiotics (days/year) [min-max] 7.5 [0.0-120.8]
    [95% IC] [12.7; 26.3]
Hospitalizations due to infection
    Number of hospitalizations (nb of patients) 6 (5)
    Median annualized nb of days/patient [min-max] 0.0 [0.0-17.7]
    [95% IC] [0.05; 1.73]
Absence from work or school due to infections
    Number of absence (nb of concerned patients) 15 (8)
    Median annualized nb of days of absence/patient (days/year) [min-maxi] 0.0 [0.0-20.0]
    [95% IC] [0.09; 1.93]
nb: number.
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and pyrexia were the most commonly reported 
treatment-emergent adverse events, occurring 
in 25.8%, 14.5% and 12.9% of the patients, 
respectively. Of note, a total of 15 episodes of 
neutropenia were reported in 8 patients 
(11.3%). All neutropenia episodes were diag-
nosed during infusion or within 72 h after infu-
sion, based on post-infusion blood samples, all 
episodes were of mild or moderate intensity 
and resolved spontaneously. These findings are 
consistent with the literature; neutropenia can 
occur following IVIG administration and is usu-
ally transient without any increase in the rate of 
infection. 
Conclusion
Immunoglobulin replacement therapy is a cor-
nerstone of the treatment of patients with PID. 
Continuous improvement in the process of 
development of human Ig allows the delivery 
of highly purified and effective Ig products. 
Advances in the mode of immune globulin 
administration, offer the possibility to individu-
alise this life-long therapy based on the patients 
clinical need and personal choices. 
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